Clinical trial evaluates lasofoxifene's effectiveness in preserving bone health and reducing metastasis in breast cancer patients, suggesting new treatment pathways.
Key Points
To investigate lasofoxifene's bone-protective properties and anti-tumor effects in estrogen receptor positive breast cancer.
Utilized animal models for ovariectomy-induced osteoporosis treatment with lasofoxifene or standard therapies.
Analyzed femurs via histology and micro-CT histomorphometry.
Evaluated anti-tumor effects in Patient-Derived Xenograft models of ER+ breast cancer.
Conducted drug synergy studies with 555 oncology drugs to identify effective combinations.
Lasofoxifene protected against hormone withdrawal-induced bone loss.
Maintained robust anti-tumor response in both primary and metastatic cancer models.
Defined rational drug combinations to enhance lasofoxifene's effectiveness.